Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

ADVM Adverum Biotechnologies Inc

6,1004

-0,0696 (-1,13%)

Zuletzt aktualisiert: 16:18:28

Verzögert um 15 Minuten

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
Von Okt 2024 bis Nov 2024

Click Here for more Adverum Biotechnologies Charts.

Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
Von Nov 2023 bis Nov 2024

Click Here for more Adverum Biotechnologies Charts.

News Adverum Biotechnologies Inc

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mittwoch 20 November 2024 (18 Stunden vor) • GlobeNewswire Inc.

Form 8-K - Current report
Montag 18 November 2024 (3 Tage vor) • Edgar (US Regulatory)

Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
Montag 18 November 2024 (3 Tage vor) • GlobeNewswire Inc.

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
Freitag 15 November 2024 (6 Tage vor) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Freitag 15 November 2024 (7 Tage vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Freitag 15 November 2024 (7 Tage vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Donnerstag 14 November 2024 (7 Tage vor) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Freitag 8 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Montag 4 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Montag 4 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones
Montag 4 November 2024 (2 Wochen vor) • GlobeNewswire Inc.

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program
Mittwoch 16 Oktober 2024 (1 Monat vor) • GlobeNewswire Inc.

Weitere Adverum Biotechnologies Inc News-Artikel

Alaunos Therapeutics

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen